MDxHealth reported flat revenue for Q3 2026 compared to the prior year, but experienced a significant widening of its operating and net losses, primarily due to increased expenses from the ExoDx acquisition. This indicates a challenging financial performance, with profitability declining despite stable top-line revenue, which could negatively impact investor sentiment.
MDxHealth's Q3 2026 earnings report reveals a concerning trend: while revenue remained flat year-over-year at $22.7 million, operating loss more than doubled to $8.1 million, and net loss increased by 26%. This deterioration in profitability is attributed to higher operating expenses following the ExoDx acquisition in September 2025. The 11% decrease in tissue-based test volume further compounds the negative outlook, suggesting potential challenges in core business growth. This news is a significant negative catalyst for MDxHealth, indicating that the acquisition has not yet translated into improved financial performance and is instead weighing on the bottom line. Traders should anticipate short-term downward pressure on MDXH stock as investors react to the widening losses and declining test volumes, questioning the immediate benefits and integration success of the ExoDx acquisition.